Jack Crawford, M.S.

Jack Crawford is the CEO of Demeetra. As CEO, Jack is focused on providing partners with commercially applicable gene editing technologies through simple accessible licenses. His role also includes developing cannabinoid-based therapeutics. Prior to Demeetra, he was at Hera BioLabs, where he successfully led a complete business pivot to spear-heading the first fully immunodeficient gene edited rat models for oncology xenografts. While serving as VP of Business Development at Transposagen, Jack was instrumental in laying the foundation for commercial applications of the piggyBac transposase, a widely adopted gene editing technology. Mr. Crawford holds a BS in Biochemistry from Virginia Tech and a Master’s in Biotechnology from University of Pennsylvania.